Maurice G. Cary, DVM, PhD, Diplomate, ACVP, Fellow IATP, Director, Pathology Experts GmbH board certified since 1989 with 38 years of industry experience has been a consultant for 23 years and based in Switzerland since 1991. His focus has been on working in/with European pharmaceutical/biotherapeutics firms (start-ups to large companies) on a range of products over this time, which provides ample opportunity to encounter a full complement of challenges one faces in developing small molecules (NCIs), biotherapeutic high molecular weight proteins (e.g., recombinant proteins, mAb), gene therapy products and stem cells. Most importantly this range of experience offers ample opportunity to encounter a multiplicity of histopathology changes one may encounter in safety assessment and discovery toxicology studies. He also has experience with a range of study designs and methods of administration, including long acting injectables. In a given year for clients he routinely performs 5-6 external peer reviews of histopathology evaluations placed at CROs, as well as prepares 2-3 Expert Reports and independent assessments of histopathology and safety data for companies, including troubleshooting and problem solving. Such assessments are most often in the context of a prescient regulatory issue, due diligence or an internal safety question. Since 2019 his company, Pathology Experts GmbH, has been supporting software companies by providing pathology expertise via annotations used to train artificial intelligence-based image analysis algorithms.